Business
AZN: Year-to-Date and Q3 2018 Results
AZN: Year-to-Date and Q3 2018 Results.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \nRNS Number : 7022G AstraZeneca PLC 08 November 2018 \n\nAstraZeneca PLC\n8 November 2018 07:00 GMT\nYear-to-Date and Q3 2018 Results\nAstraZeneca Returns to Sales Growth; New Medicines and Emerging Markets Lead the Way \n \nProduct Sales increased by 4% in the year to date (2% at CER1), supporting full-year guidance. For the quarter, Product Sales increased by 8% (9% at CER), driven by the strong performance of new medicines2 (+85%, +86% at CER) and the sustained strength of Emerging Markets (+12%, +16% at CER). Oncology sales increased by 56% in the quarter (57% at CER); China and US sales increased by 32% and 25%, respectively. The pipeline, designed to deliver sustainable growth and advances in treatment for patients, produced further positive news flow in the period; regular, additional news will continue. The Company is on track to deliver its FY 2018 Product Sales and Core EPS guidance.\n \n\n\n\n\n \n \n\n\nYTD 2018\n\n\nQ3 2018\n\n\n\n\n$m\n\n\n% change\n\n\n$m\n\n\n% change\n\n\n\n\n \n\n\nActual\n\n\nCER\n\n\nActual\n\n\nCER\n\n\n\n\nTotal Revenue\n\n\n15,673\n\n\n(6)\n\n\n(8)\n\n\n5,340\n\n\n(14)\n\n\n(13)\n\n\n\n\nProduct Sales\n\n\n15,281\n\n\n4\n\n\n2\n\n\n5,266\n\n\n8\n\n\n9\n\n\n\n\nExternalisation Revenue\n\n\n392\n\n\n(81)\n\n\n(81)\n\n\n74\n\n\n(95)\n\n\n(95)\n\n\n\n\n \n\n\n \n\n\n \n\n\n \n\n\n \n\n\n \n\n\n \n\n\n\n\nReported Operating Profit3\n\n\n2,310\n\n\n(23)\n\n\n(20)\n\n\n851\n\n\n(26)\n\n\n(21)\n\n\n\n\nCore Operating Profit4\n\n\n3,480\n\n\n(31)\n\n\n(31)\n\n\n1,319\n\n\n(29)\n\n\n(26)\n\n\n\n\n \n\n\n \n\n\n \n\n\n \n\n\n \n\n\n \n\n\n \n\n\n\n\nReported Earnings Per Share (EPS)\n\n\n$0.88\n\n\n(34)\n\n\n(34)\n\n\n$0.34\n\n\n(37)\n\n\n(36)\n\n\n\n\nCore EPS\n\n\n$1.88\n\n\n(37)\n\n\n(37)\n\n\n$0.71\n\n\n(37)\n\n\n(33)\n\n\n\n\n \nPascal Soriot, Chief Executive Officer, commenting on the results said:\n\"Today marks an important day for the future of AstraZeneca, with the performance in the quarter and year to date showing what we expect will be the start of a period of sustained growth for years to come. Commercial execution has been exceptional and our new medicines are now firmly established as the drivers of growth, supporting our continued success in Emerging Markets.\n \nThese n...